Genetic variation of the 5‐HT1A rs6295, 5‐HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients
Brain and Behavior · 2023
DOI: 10.1002/brb3.3323 ↗Kurz gefasst
Fachartikel in der Zeitschrift Brain and Behavior, 2023. Verfasst von Jasmin Obermanns und 6 weiteren Autor:innen. Beteiligte Einrichtung: LWL University Hospital, Department of Psychiatry, Psychotherapy and Preventive Medicine, Ruhr University Bochum, Bochum, Germany. Hauptthemen laut MEDLINE: Endocannabinoids, Polyunsaturated Alkamides. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 73 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: FoRUM Research Programme of the Faculty of Medicine, Ruhr University Bochum.
Abstract (Originalsprache)
Background
The reasons for developing depression are not fully understood. However, it is known that the serotonergic system plays a role in the etiology, but the endocannabinoid system receives attention.
Method
In this study, 161 patients with a depressive disorder and 161 healthy participants were examined for the distribution of the CNR1 rs4940353, 5‐HT2A rs6311, and 5‐HT1A rs6295 by high‐resolution melting genotyping. The concentration of arachidonoyl ethanolamide (AEA) and 2‐arachidonoylglycerol (2‐AG) in the blood was measured by liquid chromatography–tandem mass spectrometry. Additionally, depression and anxiety symptoms were evaluated based on self‐questionnaires. Fifty‐nine patients participated in a second appointment to measure the concentration of AEA, 2‐AG, and symptoms of depression and anxiety.
Results
We observed higher AEA and decreased 2‐AG concentrations in patients with depression compared to healthy participants. During the treatment, the concentrations of AEA and 2‐AG did not change significantly. In patients higher symptoms of anxiety correlated with lower concentrations of 2‐AG. Gender differences were found concerning increased 2‐AG concentration in male patients and increased anxiety symptoms in female patients. Genotypic variations of 5‐HT1A rs6295 and 5‐HT2A rs6311 are associated with altered serotonergic activity and serotonin content in patients.
Conclusion
In conclusion, it seems that the endocannabinoid system, especially the endocannabinoids 2‐AG and AEA, and genetic variations of the 5‐HT1A and 5‐HT2A could play a role in patients with depression and may be involved in a depressive disorder.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- LWL University Hospital, Department of Psychiatry, Psychotherapy and Preventive Medicine, Ruhr University Bochum, Bochum, Germany.
- Chemistry and Biochemistry of Natural Products, Ruhr University Bochum, Bochum, Germany.
ORCID-Profile: Cynthia Segura Vesterager, Frank Schulz, Barbara Emons
Förderung
- FoRUM Research Programme of the Faculty of Medicine, Ruhr University Bochum
Zitieren
APA
Obermanns, J., Meiser, H., Hoberg, S., Vesterager, C. S., Schulz, F., Juckel, G., & Emons, B. (2023). Genetic variation of the 5‐HT1A rs6295, 5‐HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients. Brain and Behavior. https://doi.org/10.1002/brb3.3323
Vancouver
Obermanns J, Meiser H, Hoberg S, Vesterager CS, Schulz F, Juckel G, et al. Genetic variation of the 5‐HT1A rs6295, 5‐HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients. Brain and Behavior. 2023. doi:10.1002/brb3.3323
BibTeX
@article{Obermanns2023,
author = {Obermanns, Jasmin and Meiser, Hanna and Hoberg, Saskia and Vesterager, Cynthia Segura and Schulz, Frank and Juckel, Georg and Emons, Barbara},
title = {Genetic variation of the 5‐HT1A rs6295, 5‐HT2A rs6311, and CNR1 rs1049353 and an altered endocannabinoid system in depressed patients},
journal = {Brain and Behavior},
year = {2023},
doi = {10.1002/brb3.3323}
}
EUVIMED